Efectos sobre la prdida de peso, composicin corporal y prevencin de diabetes El programa SURMOUNT muestra que TZP reduce el peso de forma dosis-dependiente, alcanzando un 22,5% de reduccin ponderal con la dosis mxima semanal de 15mg40 (tabla 1)
The secondary renal outcomes from CVOTs with GLP-1 receptor agonists (RAs) consistently show benefit in DKD, largely through restricting the progression of albuminuria (Kristensen et al, 2019)
Current pricing, program details, and eligibility information are available at refills.com
Experience the program Membership that moves you forward, together See how APhA supports pharmacy professionals through real challenges and why this community matters
According to the American Diabetes Association, high blood glucose levels and being overweight translates to greater risk of developing complications